Mehis Pold, M.D.

12277 Caminito Mira Del Mar, San Diego, CA 92130

C 310.383.1561, H 858.259.5408, mp580d1a@westpost.net,

PROFILE
Director / Associate Director, Program / Project Manager, Senior/Principal Scien
tist
Molecular diagnostics, biomarkers, gene-expression analysis, high-throughput tec
hnologies, serum autoantibody profiling, early stage cancer drug development, le
adership
Action-oriented executive possessing wealth of experience in biotechnology and a
cademic settings. Very strong management and leadership skills with the ability
to build data and human systems to achieve organizational goals. Highly organiz
ed. Very strong communication skills, both written and verbal. Multi-lingual.
* Skilled in managing new technology development
* Experienced in project management, and building international R&D teams
* Highly knowledgeable about bioinformatics and data-mining for novel biomarkers
* Expert in troubleshooting puzzling experimental inconsistencies
* Successful at writing peer-review papers, winning grants, and conference prese
ntations
* Strong at translating experimental medicine into clinical context
* Capable of building websites, creating flash movies for on-line advertising an
d marketing campaigns
* Proficient with FDA requirements for in vitro diagnostic devices and CLSI stan
dards
EXPERIENCE
Protobios O, Estonia, EU 2009-Present
Molecular diagnostics R&D biotech start-up specializing in oncology and auto imm
une disease. 24 employees.
Director, Molecular Diagnostics & Biomarkers
Reports to the CEO and CSO. Responsible for the design and execution of the com
panys molecular diagnostics strategies. Summarized progress reports for executi
ve management. Drafted and executed quarterly plans. Executed timely planned act
ivities. Determined the clinical need for planned molecular diagnostics products
. Contributed to small business grant writing efforts. Managed a group of 7 res
earch scientists and built a strong R& D team spirit. Implemented standardized w
orkflow and quality controls for R&D diagnostics.
* Enhanced existing technology of diagnostic biomarker discovery and personalize
d medicine; Result: Designed and implemented an ultra-high throughput technology
platform
* Coordinated proof-of-principle experiments for Global Mimotype Mapping (GMM) t
echnology; Result: Provisional Patent Global Mimotope Mapping (GMM) to determine
the state of human and animal health related to the immune memory: artificial i
ntelligence in human health management.
* Delivered standardized workflow for diagnostic serum autoantibody discovery by
phage display; Result: novel diagnostic markers for type 1 diabetes.
* Currently writing a Grant for technology development; Result: Grant in process
of completion prior to submission to European Union Granting Agencies.

MannKind Corporation, Valencia, CA 2007-2009

Public company specializing in fast-acting pulmonary insulin, cancer immunothera
pies. 500 employees. $60-million revenues.
Senior Scientist
Reported to the R&D director. Managed research associates. Biologically validat
ed MannKind anti-cancer small-molecule targets. Contributed to cancer target pip
eline. Made presentations at companys R&D management meetings.
* Built a cancer gene-expression database; Result: Acquired a tool that provided
an additional rational element to the companys drug design efforts.
* Designed and implemented biological tests for small molecule targets; Result:
provided biological rationale small molecule targeting of tumor IRE1.
* Stratified multiple myeloma bone marrow cancer related to company anti-cancer
small molecules; Result: Discovery of the non-IgG multiple myeloma as most respo
nsive to proteasome inhibitors.
CeMines, Inc., La Jolla, CA 2004-2006
Privately-held company specialized in molecular cancer diagnostics research and
development. 20 employees.

Mehis Pold, M.D. C 310.383.1561 Page 2

Director of Development, Molecular Medicine

Reported to the Chief Scientific Officer. Responsible for managing 5 scientists
and research associates. Designed multivariate cancer diagnostics strategy. Ma
de presentation at World Biomarker Congress.
* Wrote patents; coordinated with patent attorneys; Result: Won International pa
tent: Mehis Polc & Toomas Neuman: Composition and Methodology for Classifying Bi
ological Samples, International Patent #WO 2006/091734 A2.
* Worked on image analysis software design, diagnostic trial statistical design
and 510K applications; Result: Custom software for automated immunoassay image a
nalysis, and 510K application CeMines CellCorrect Lung Cancer Autoantibody Detec
tion Kit
* Established a collaboration with UCLA Lung Cancer SPORE program. Result: Condu
cted presentation at 13th Annual NIH SPORE Investigators Workshop;
UCLA, Division of Pulmonary and Critical Care Medicine, Los Angeles, CA 2000-
2004
Leading academic institution. Jonson Comprehensive Cancer Center Pulmonary Immun
ology Laboratory.
Assistant Researcher / Junior Faculty
Reported to the Chief of Pulmonary Medicine Division. Responsible for writing a
nd applying for grants to fund the research at Pulmonary Immunology Lab of UCLA.
Conducted experiments on lung cancer biology and anti-cancer pharmacology. Su
pervised research assistants. Made presentations at seminars and national cance
r conferences. Published in scientific journals. Assisted in peer-review of man
uscripts submitted for review to the faculty of Pulmonary medicine.
* Introduced whole-genome analysis gene-expression analysis at Pulmonary Immunol
ogy lab; Result: Identified new oncology targets for R&D; won a grant from the A
merican Lung Association.
* Wrote and submitted materials for a grant; Result: Won peer-review grant Ident
ification of biomarkers by mass spectroscopy and peptide arrays for early diagno
sis of lung cancer from UCLA Lung Cancer SPORE.
* Authorship of 13 peer-review papers; Result: Published in highly-ranked peer r
eview journals, including Cancer Research, The Journal of Biochemistry, FASEB Jo
urnals.
Department of Veterans Affairs, Div. Hem-Oncology, West Los Angeles, CA 1995-
2000
Division specialized in medical services and biomedical research.
Fellow of The Lymphoma Research Foundation of America, 1999-2000
Reported to the Chief of Hematology and Oncology Division.
* Demonstrated that (1) MAGE-family tumor antigens evolved from an ancestral MAG
E-gene first found in fruit fly Drosophila melanogaster.
* Co-authored a study in Science magazine about the role of Kaposis sarcoma viru
s (HHV8) in pathogenesis of multiple myeloma.
* Wrote a fellowship; Result: Won fellowship from The Lymphoma Research Foundati
on of American The Role of BCL-1 and Immunoglobulin Heavy Chain Loci in B-Cell T
ransformation.
Postdoctoral Researcher, 1995-1999
Responsible for the study of chromosomal abnormalities of bone marrow cancer mul
tiple myeloma, as well as the role of Kaposis sarcoma virus in pathogenesis of m
ultiple myeloma. Presented research at cancer conferences. Designed and execut
ed experimental research on multiple myeloma.
* Authorship on a paper published in the foremost science journal, Science.
* Cloned multiple myeloma breakpoint on chromosome 11q13; Result: Won Fellowship
from The Lymphoma Research Foundation of America.
* Presentations at the national cancer conferences: American Society of Hematol
ogy, 1997 and 1998.
* Chance discovery of HIV in a bone marrow of a volunteer donor.
EDUCATION
M.D., University of Tartu, Estonia, EU
* Medicine

Mehis Pold, M.D. C 310.383.1561 Page 3

PUBLICATIONS
1. Heuze-Vourch N, Liu M, Dalwadi H, Baratelli F, Zhu L, Goodglick L, Pld M, Sha
rma S, Ramirez R, Shay J, Minna JD, Strieter RM, Dubinett SM. IL-20, an anti-ang
iogenic cytokine that inhibits COX-2 expression. Biochem & Biophys Res Comm 2005
; 333:470475
2. Pld M, Krysan K, Pld A, Dohadwala M, Heuze-Vourch N, Mao JT, Riedl KL, Sharma
S, M. Dubinett SM. Cyclooxygenase-2 (COX-2) Modulates The Insulin-like Growth F
actor (IGF)-axis in Non-SmallCell Lung Cancer (NSCLC). Cancer Res. 2004; 64:6549
-55
3. Krysan K, Dalwadi H, Sharma S, Pld M, Dubinett S. COX-2-dependent expression
of survivin is critical for apoptosis resistance in NSCLC. Cancer Res. 2004; 64:
6359-62
4. Riedl KL, Krysan K, Pld M, Dalwadi H, Heuze-Vourch N, Dohodwala M, Liu M, Cui
X, Figlin R, Sharma S, Dubinett SM. Update on Cyclooxygenase-2 in Lung Cancer.
Drug Resistance Updates 2004; 7:169-84. Review
5. Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourch N, Goodglick L, Merc
hant F, Seligson D, Pld M, Strieter R, Sharma S, Dubinett S. Cyclooxygenase-2-de
pendent expression of survivin in non-small cell lung cancer. Chest. 2004;125:14
0S
6. Pld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Pold A, Luo J, Krysan K,
Dohadwala M, Mao JT, Batra RK, Strieter RM, Dubinett SM. Cyclooxygenase-2-depend
ent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and inter
leukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res. 2004;64:1853-60
7. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourch N, Pld
M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. CO
X-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J.
2004;18:206-8
8. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pld M, Mao JT. Cyclooxygenase-2
in lung cancer. Prog Exp Tumor Res. 2003;37:138-62
9. Batra RK, Lin Y, Sharma S, Dohadwala M, Luo J, Pld M, Dubinett SM. Non-small
cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymp
hocytes through an I kappa B kinase-dependent mechanism. Cancer Res. 2003;63:642
-6
10. Sharma S, Huang M, Dohadwala M, Pld M, Batra RK, Dubinett SM. Cyclooxygenas
e 2-dependent regulation of antitumor immunity in lung cancer. Methods Mol Med.
2003;75:723-36
11. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pld M, Sharma S, Dubinett SM.
Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer c
ells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent
invasion. J Biol Chem. 2002;277:50828-33
12. Pld M, Dohadwala M, Luo J, Lin Y, Dubinett S. Microarray identifies cyclo-ox
ygenase-2-dependent modulation of insulin-like growth factor binding protein-3 i
n non-small cell lung cancer cells. Chest. 2002;121:29S
13. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pld M, Ba
tra RK, Dubinett SM. Non-small cell lung cancer cyclooxygenase-2-dependent invas
ion is mediated by CD44. J Biol Chem. 2001;276:20809-12
14. Ma HJ, Sjak-Shie NN, Vescio RA, Kaminsky M, Mikail A, Pld M, Parker K, Beksa
c M, Belson D, Moss TJ, Wu CH, Zhou J, Zhang L, Chen G, Said JW, Berenson JR. Hu
man herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from
multiple myeloma patients: a shared pattern not found in Kaposis sarcoma or pri
mary effusion lymphoma. Clin Cancer Res. 2000;6:4226-33
15. Pld M, Pold A, Ma HJ, Sjak-Shie NN, Vescio RA, Berenson JR. Cloning of the f
irst invertebrate MAGE paralogue: an epitope that activates T-cells in humans is
highly conserved in evolution. Dev Comp Immunol. 2000;24:719-31
16. Pld M, Zhou J, Chen GL, Hall JM, Vescio RA, Berenson JR. Identification of a
new, unorthodox member of the MAGE gene family. Genomics. 1999;59:161-7
17. Rettig MB, Ma HJ, Vescio RA, Pld M, Schiller G, Belson D, Savage A, Nishikub
o C, Wu C, Fraser J, Said JW, Berenson JR. Kaposis sarcoma-associated herpesviru
s infection of bone marrow dendritic cells from multiple myeloma patients. Scien
ce. 1997;276:1851-4